Federal contract award

75N91024C00009

SBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICS

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Health and Human Services
OfficeNIH NCI
NAICS541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSCAN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Parent award / vehicleNot reported
Set-asideSMALL BUSINESS SET ASIDE - TOTAL
Pricing typeFIRM FIXED PRICE
Obligations$355.0K
Current contract value$355.0K
Potential contract value / ceiling$355.0K
Start dateFeb 15, 2024
Current end dateApr 14, 2025
Potential end dateApr 14, 2025
Latest award activityFeb 11, 2025
Source loadedAug 15, 2026

Funding and modification history

Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Feb 11, 2025P00003$0SBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICS
Oct 15, 2024P00002$0SBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICS

Buyer contacts from matching notices

Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.

ContactRolePublished contact methodsEvidenceSource date
Cherie WellsContactncioasbir@mail.nih.govSourceMar 13, 2023
Randall TiquiContactRandall.Tiqui@nih.govSourceMar 13, 2023
Cherie WellsContactncioasbir@mail.nih.govSourceFeb 27, 2023
Mandie WhiteContactWhitems@mail.nih.govSourceFeb 27, 2023

Research next steps

  1. Check the stated set-aside against the solicitation and current certifications.
  2. Review the award scope and buyer evidence before making a bid/no-bid decision.